

HALF YEAR RESULTS PRESENTATION

For the six months ended 31 January 2018



The following presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated (“relevant persons”). Any person who is not a relevant person should not act or rely on this presentation or any of its contents. This presentation does not constitute an offering of securities or otherwise constitute an invitation or inducement to any person to underwrite, subscribe for or otherwise acquire securities in Nanoco Group PLC or any of its subsidiaries (“Nanoco”).

It should be noted that past performance cannot be relied on as a guide to future performance. This presentation contains forward-looking statements with respect to Nanoco’s plans and objectives regarding its financial conditions, results of operations and businesses.

The financial information referenced in this presentation does not contain sufficient detail to allow a full understanding of Nanoco’s results. For more detailed information, the entire text of the interim results announcement for the half year ending 31 January 2018, can be found on the Investor Relations section of the Nanoco website (www.nanocogroup.com).


Momentum in current trading

- Game changing Material Development and Supply Agreement with a large US-listed Corporation for advanced electronic devices
- Increasing number of Nanoco equipped displays products moving through to commercial production with
 - First display products expected to be in the market during 2018
- Signed Commercial Supply and License Agreement for use of Company's products in US corporation, CareWear's® light therapy medical devices
- Made progress in Specialised Horticultural Lighting and Life Sciences
- Increased number of granted patents and patent applications to c.600

Strengthened financial position

- Strengthened balance sheet by £8 million with placing
- Revenue and other operating income for the six months was £0.3 million (2017: £0.8 million) and the loss after tax was reduced to £4.2 million (2017: £5.4 million)
- Cash and cash on deposit at 31 January 2018 was £8.7 million (31 July 2017: £5.7 million; 31 January 2017: £8.3 million)

COMPANY OVERVIEW – PIONEER AND WORLD LEADER




- Pioneer and world leader in the development and production of cadmium-free quantum dots (CFQDs)
- Platform technology enables revenue from multiple, large addressable markets
- Extensive patent portfolio, c.600 patents granted/pending
- Large addressable markets
- R&D in Manchester
- Manufacturing in Runcorn
- c.80 staff

STRENGTHS



**Leader in heavy-metal-free
CFQD® quantum dot & Nano-
material products**

Leading R&D innovation
Intellectual property




Scalable production process

Molecular seeding process
Efficient scalable production




- Leading performance
- High quality
- Reliability
- Low risk
- High volume
- Cost competitive





NANO-MATERIALS

NANO-MATERIALS – GAME CHANGING

- Move from traditional, costly semiconductor processing to increased functionality in nano-particles
- Nano particle development is a core competency of Nanoco
 - Complex particle design and development
 - Scale up
 - Mass production
- Focus on new generations of infrared quantum dots
- Technology developed for Nanoco's solar programme relevant
- Applications in advanced electronics, sensing and autonomous vehicles
- Focus on human – machine, machine – environment interfaces
- Delivering major contract with US corporation signed in February 2018





DISPLAY



GROWING DISPLAY MARKET OPPORTUNITY

- Benefits of CFQDs
 - Enables Wide Color Gamut (WCG) displays for 4K, UHD, HDR, gaming, streaming, photos
 - Integrated into existing LCD technology
 - Consistent and accurate colours across product range
 - Improved peak brightness and contrast
 - Lightning fast response times and refresh rates
- Samsung leading the way with its QLED brand; other OEMs following
- Nanoco technology demonstrated at industry shows, Touch Taiwan and CES by top 5 LCD panel manufacturer
- Increasing number of Nanoco equipped display products moving through to commercial production with customers in Asia
- First products expected to be in the market in 2018
- Nanoco and its licensees, Dow and Merck, are the only commercial suppliers of CFQDs; competition chasing cadmium-free hard



AUO demonstrating 65", 75" and 85" UHD HDR cadmium free QD TVs at Touch Taiwan in September 2017


MULTI-CHANNEL STRATEGY TO DISPLAY SUCCESS

Nanoco Non-exclusive Licensees




Potential Display Customers





- Focused on Taiwanese OEMs with near term potential
- Sales process has taken longer than anticipated
 - Customisation required for each OEM
 - Achieving required specification can be iterative
 - Goalposts frequently changed
 - Use of cadmium lingering
- Product expected in the market in 2018


CONTINUOUS INNOVATION CRITICAL TO SUCCESS



Current technology





2 – 4 years away



4+ years away





OTHER MARKETS

HORTICULTURE LIGHTING

- Our technology is being commercialised today
 - Commercial Supply and License Agreement with the Sports Turf Research Institute
 - Lights being trialled by leading UK grower for large vertical farm investment
- As the world's population continues to grow and is focused increasingly in urban environments, new farming models, such as vertical farming will be required
- Consumers are becoming more conscious about where and how their food is produced and transported
- The horticultural lighting market is forecast to grow from \$3.8bn in 2017 to \$17.0bn in 2027 (source Yole Développement)
- CFQD lights tuned to match the ideal growing conditions for plants
- Benefits include faster growth, energy efficient, changing wavelength without changing the LED




GE Mirai Lettuce Farm in Japan




Nanoco lights undergoing extensive trials at leading UK grower




- Focus on cancer imaging and diagnostics
- Recent CRO test results show Nanoco CFQD image agent is non-mutagenic, using industry standard AMES testing, required by regulatory guidelines
- Partnership in place with Covance “CRO”, University College London, University of Manchester and University of Nottingham
- Positive results :
 - Vastly improved demarcation of lymph nodes in animal models compared to standard practice
 - No signs of toxicity were observed in rodents after high doses. Work is ongoing
 - Active conjugates against several tumour markers
 - Significant enhancement of cancer cell labelling with 5-ALA
- Supported by Innovate UK Grant
- Strong IP portfolio



In vivo photoluminescence images of lymph nodes in mice




*spheres
labelled with
streptavidin-
Vivodot™
green and red
conjugates*



*Breast cancer cells
labelled with Herceptin-
Vivodots™ red conjugate*

NEXT GENERATION 2D AND OTHER NEW MATERIALS

- 2D material development programme
 - Partnership between Nanoco and University of Manchester, National Graphene Institute
 - Collaboration between Nobel Laureate Prof. Kostya Novoselov and Nanoco
 - Develop and commercialise future generations of materials
 - Funded through collaboration agreement
 - Applications for new catalysts, photo-detector, photovoltaics, light-emitting devices, inverters and logic gates
- Electroluminescent and other materials
 - New generation of electroluminescent QDs which compete directly with OLED materials for new generations of display
 - Complex combination of materials in partnership with world leading technology companies



Next-generation hetero structure devices:
photodetectors, photovoltaics, light-
emitting devices, field-effect transistors,
inverters and logic gates

OPERATIONS




EXPANDING MANUFACTURING TO FULFIL COMMERCIAL SALES


- Expanding Runcorn production to service new and growing nano-materials business
- Expansion fully funded by customer
- Runcorn currently fulfilling commercial display orders
- Displays capacity of 1 million TV/year (55inch) with 24/7 operation
- ISO 9001 certified
- Aggressively reducing product cost

Runcorn Production Facilities

Display Fab




Nano-material Fab



FINANCIAL REVIEW






FINANCIAL HIGHLIGHTS


	H1 2018	H1 2017	Movement
	£m	£m	£m
Revenue and other income	0.3	0.8	(0.5)
R & D investment	1.9	2.9	(1.0)
LBITDA	(4.3)	(5.9)	1.6
Loss after tax	(4.2)	(5.4)	(1.2)
Cash and short term deposits	8.7	8.3	0.4
Deferred revenue	0.6	0.8	(0.2)
Net assets	14.3	14.1	0.2
	No	No	No
Patents granted/pending at year end	600	550	50
Employees	80	93	(13)

- Not included in the £8.74m cash are accrued R&D tax credits, the upfront milestone payment and capex funding from our new US partner


MOVEMENT IN NET LOSS DURING H1 2018



MOVEMENT IN OPERATING COSTS COMPARED TO H1 2017



MOVEMENT IN CASH H1 2018





SUMMARY

SUMMARY – MOMENTUM IN CURRENT TRADING

- Platform technology enables revenue from multiple, large addressable markets
- Game changing Material Development and Supply Agreement with a large US-listed Corporation for advanced electronic devices
- Runcorn manufacturing expansion underway to support new commercial contracts
- Display
 - Increasing number of Nanoco equipped products moving through to commercial production
 - First display products expected to be in the market during 2018
 - Next gen products in development
- Other markets
 - Opportunities emerging in Horticultural Lighting, Medical Devices and Life Sciences
 - Commercial agreement signed with a US medical device company under the brand name, CareWear®
 - 2D and other new materials being developed
- Large and growing patent portfolio
- Cost base significantly reduced and balance sheet strengthened
- Sufficient cash to support growth



QUESTIONS


Q&A

APPENDICES




WHAT IS A QUANTUM DOT?

- Tiny particles of a fluorescent semiconductor material
- 1 to 10 nanometers in diameter
- Size of the quantum dot determines the spectrum of light emitted
- Smaller = blue; larger = red
- Can be tuned to light beyond visible light into the Infra-red or ultra-violet parts of the spectrum



**Established
technology with a
wide range of
commercial
applications**

BENEFITS OF CFQD® QUANTUM DOT FILM



Better Colour Gamut



- Much improved colour saturation
- Improved colour enhancement over LCD → similar to OLED

Energy Efficient




- Narrow bandwidth = more light extraction through colour filters
- Enables use of blue LED instead of less efficient white LED

Minimal Process Change

- Uses existing LCD manufacturing infrastructure
- Uses existing LCD supply chain



BREAKDOWN OF A QD LCD DISPLAY



Emits light – much more blue than green and red

Light energises the quantum dots in the film

Quantum dots emit precise green and red colours

LCD panel creates the image through polarised shuttering of pixels

Each pixel / shutter is paired with a coloured filter to remove all but the red, green or blue light. Filters may be replaced by QDs in the future.

WHAT PEOPLE ARE SAYING ABOUT QD DISPLAYS

“A TV screen that is jaw-droppingly good”
- *The Independent*



“TVs are entering a new era in 2017”
- *Trusted Reviews*



“May be the holy grail of gaming displays”
- *Forbes*




“CF791’s pitch-perfect colors change the game for ultrawides”
- *Monitornerds.com*




Digital Trend
4.9 out of 5

CADMIUM-FREE TO DOMINATE RAPIDLY GROWING MARKET

QD Film revenue by Application




QD Material Revenue Breakdown




COMPETITION AND SUPPLY

- Nanoco and its licensees, Dow and Merck, are the only commercial suppliers of CFQDs
- Competition chasing cadmium free hard



LCD TV MARKET SHARE 2016



Source: Statista

RoHS UPDATE

- Cadmium-based quantum dots are currently banned in lighting and will be effectively banned in displays from 31st October 2019, since the normal RoHS limit of 100ppm will apply once the exemption ends
- Nanoco expects that regulations in other key markets, including China, will fall in line with RoHS
- Meanwhile, our contacts with display companies indicate that most already accept the need for new display products to be cadmium-free - especially the world leading brands in both television, computer monitor and laptop displays
- The EU Commission has started an 18 month project to review the list of toxic substances that are restricted under RoHS regulations and to review how to evaluate Exemption requests.
- Indium Phosphide (InP) is included in the list of materials to be considered for future inclusion in the RoHS restricted materials list because it is rated as a probable carcinogen. It is much less harmful than Cadmium and does not persist in the environment
- Nanoco does not use InP in its CFQD[®] quantum dots, which have been tested and shown to be non-toxic for potential medical use in cancer treatments
- The EU Commission has also included in this package of work one new request for Cadmium based QDs to be used in 'on-chip' LED lighting applications
- Nanoco will actively participate in the review process for the proposed RoHS changes and continue to champion the use of safer alternatives to Cadmium



Market leader Samsung promotes their cadmium-free quantum dots QLED TV range at CES 2017

LEADERSHIP

Dr Christopher Richards Non-Executive Chairman

- CEO, Non-Executive chairman, Arysta LifeSciences
- 20 years of increasing management roles at Syngenta
- Executive chairman of Plant Health Care
- NED of Origin Enterprises plc

Dr Michael Edelman CEO

- Led spin-out of Nanoco from University of Manchester
- GE/Bayer JV, founded www.yet2.com Europe, commercial director Colloids Ltd, Brunner Mond, ICI

Dr Nigel Picket Co-founder & CTO

- Inventor of Nanoco's key patented scale-up technology
- Leading expert on semi-conducting nano-crystals
- Japanese Government, St. Andrews University, Georgia Tech

David Blain CFO

- Experienced Quoted Company CFO, Renovo, Drew Scientific, Price Waterhouse

Keith Wiggins COO

- Increasing business & corporate leadership roles over years at Dow and ICI
- Business builder; former CEO of Haltermann, MD Dow Norther Europe, director roles speciality businesses located in USA, Germany, Switzerland, Hong Kong and United Kingdom

Brendan Cummins Senior Non-Executive

- 40 years of industry experience mostly with Ciba Geigy, last role was CEO of Ciba and led the sale of Ciba to BASF
- Board of US Headquartered, Ashland Inc., Chair of Governance and Nominations Committees and member of Audit Committee
- Board of Perstorp AB, Sweden

Dr Alison Fielding Non-Executive

- Director of Strategy and IP Impact at IP Group
- NED of Getech Group plc
- Astra Zeneca, followed McKinsey & Co, then co-founded Techtran Group Limited which was acquired by IP Group in 2005 and subsequently held the role of director and COO at IP Group
- Board member and advisor of several early stage and quoted IP Group backed technology companies

STATEMENT OF COMPREHENSIVE INCOME

	2018 £'000	2017 £'000
Revenue	196	676
Cost of sales	(59)	(36)
Gross profit	137	640
Other operating income	59	142
Operating expenses		
Research and development expenses	(1,888)	(2,873)
Administrative expenses	(3,143)	(4,347)
Operating loss	(4,835)	(6,438)
- before share-based payments and the costs of the move to the Main Market	(4,710)	(6,198)
- share-based payments	(125)	(240)
Finance income	-	35
Loss on ordinary activities before taxation	(4,835)	(6,403)
Taxation	630	975
Loss on ordinary activities after taxation for the year and total comprehensive loss for the year	(4,205)	(5,428)
Loss per share		
Basic and diluted loss for the year	(1.63)p	(2.28)p

STATEMENT OF FINANCIAL POSITION

	31 January 2018 Group £'000	31 January 2017 Group £'000
Assets		
Non-current assets		
Tangible fixed assets	634	1,106
Intangible assets	3,234	2,820
	3,868	3,926
Current assets		
Inventories	132	238
Trade and other receivables	925	1,013
Income tax asset	2,467	2,945
Short-term investments and cash on deposit	-	5,000
Cash and cash equivalents	8,744	3,328
	12,268	12,524
Total assets	16,136	16,450
Liabilities		
Current liabilities		
Trade and other payables	1,210	1,526
Deferred revenue	102	207
	1,312	1,733

STATEMENT OF FINANCIAL POSITION

	31 January 2018 Group £'000	31 January 2017 Group £'000
Non-current liabilities		
Deferred revenue	501	597
	501	597
Total liabilities	1,813	2,329
Net assets	14,323	14,120
Capital and reserves		
Issued equity capital	66,565	58,602
Share-based payment reserve	3,082	2,955
Merger reserve	(1,242)	(1,242)
Retained earnings	(54,082)	(46,195)
Total equity	14,323	14,120

STATEMENT OF CASH FLOW

	31 January 2018 Group £'000	31 January 2017 Group £'000
(Loss)/profit before tax	(4,835)	(6,403)
Adjustments for:		
Net finance income	-	(35)
Depreciation of tangible fixed assets	266	393
Amortisation of intangible assets	268	186
Share-based payments	125	240
Changes in working capital:		
Decrease in inventories	(56)	(30)
Decrease/(increase) in trade and other receivables	(256)	1,054
(Decrease)/increase in trade and other payables	(108)	(917)
(Decrease)/increase in deferred revenue	(51)	(375)
Cash outflow from operating activities	(4,535)	(5,887)
Research and development tax credit received	-	-
Overseas corporation tax paid	-	-
Net cash outflow from operating activities	(4,535)	(5,887)

STATEMENT OF CASH FLOW

	31 January 2018 Group £'000	31 January 2017 Group £'000
Cash flow from investing activities		
Purchases of tangible fixed assets	(7)	(239)
Purchases of intangible fixed assets	(376)	(583)
Decrease in cash placed on deposit	-	-
Interest received	-	13
Net cash inflow from investing activities	(383)	(809)
Cash flow from financing activities		
Proceeds from issues of ordinary share capital	7,956	545
Interest paid	-	-
Loan repayment	-	(32)
Net cash inflow/(outflow) from financing activities	7,956	513
(Decrease)/increase in cash and cash equivalents	3,038	(6,183)
Cash and cash equivalents at the start of the year	5,706	9,511
Cash and cash equivalents at the end of the year	8,744	3,328
Monies placed on deposit at the end of the year	-	5,000
Cash, cash equivalents and deposits at the end of the year	8,744	8,328

SHAREHOLDER ANALYSIS (AS AT 31 JANUARY 2018)

Name	Shareholding	Percentage
Lombard Odier	59,024,089	20.64
Hargreaves Lansdown Asset Management	24,846,180	8.69
Cogefi Gestion	18,862,117	6.60
Baillie Gifford & Co	15,976,767	5.59
Miton Asset Management	15,403,765	5.39
Dr Nigel Pickett (CTO)	11,112,347	3.89
Interactive Investor	10,487,584	3.67
Dr Michael Edelman (CEO)	4,974,350	1.74

Notes: The total number of voting rights in the Company is 285,934,927



Nanoco Group PLC

46 Grafton Street, Manchester, M13 9NT, United Kingdom,
Tel: +44 161 603 7900 | Fax: +44 161 603 7901
info@nanocotechnologies.com
www.nanocogroup.com